The Thailand Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 26.6%, reaching USD 2.6 million in 2031 from USD 0.8 million in 2026.
Continuous glucose monitoring, or CGM, is a wearable medical device that continuously tracks blood sugar levels for people with type 1 and type 2 diabetes. Tracking blood sugar levels is extremely essential for diabetic patients as they have to make sure when to take insulin, and CGM devices help them in determining that. CGM is a widely used technology as it is advantageous for diabetics. Studies have shown that the use of CGM devices ensures a shorter duration of hypoglycemia or a lower level of glycated haemoglobin. In Thailand, the continuous glucose monitoring market is segmented by application and end-user.
The growing prevalence of type 1 and type 2 diabetes, continuous product launches by key market players, along with rising government initiatives and programmes to educate people about diabetic healthcare, are some of the key determinants that are positively impacting the demand for CGM devices in this country.
However, the high price of CGM devices and the lack of reimbursement policies by the medical insurance provider in this region are obstructing the growth of the Thai market for continuous glucose monitoring devices during the analysis period.
During the anticipation period, the growing incidence of diabetes will support the growth of the Thailand continuous glucose monitoring market during the projection period.
One of the primary factors driving the growth of continuous glucose monitoring devices in Thailand is the high prevalence of type 1 and type 2 diabetes among the population. According to the statistics presented by the International Diabetes Federation, 9.7 per cent of Thai adults, or more than 6 million people, had diabetes in 2021. This number is expected to reach 6.7 million by 2045. Moreover, 8.5 million people have impaired glucose tolerance in this country, which puts them at a greater risk of developing type 2 diabetes. This number is anticipated to reach 8.6 million by 2045.
Those who have diabetes run the risk of significant and fatal consequences like heart attack, kidney failure, blindness, and lower limb amputation. This leads to a lower quality of life and higher medical expenditure. The prevalence of diabetes has alarmingly increased across China in recent years, reaching an all-time high, mostly due to lifestyle changes. Diabetes is also one of the leading causes of death in Thailand. According to IDF data, nearly 1.4 million people died due to diabetes. Diabetic patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. Therefore, CGM devices are extremely crucial for them. The decreasing cost of CGM devices in the country is also propelling market demand.
Various policies, programs, and services related to diabetes are being implemented by the government to spur growth during the projection period.
To combat risk factors like obesity and other medical conditions, the Thai government has implemented several reforms over the years to improve the distribution of doctors, create new types of service organisations, introduce new financing models, and implement a variety of quality improvement initiatives and policy frameworks in the healthcare sector. This also emphasizes chances for sustaining and growing advancements in the provision of diabetes care and the application of diabetes technologies.
Initiatives implemented by the Thai government are anticipated to fuel the market's expansion. In order to assure cheap pricing for devices, the Indian Federal Government collaborated with a large number of private businesses to use their supply chain. With the introduction of new technologies, continuous glucose monitoring devices are becoming more affordable, which is projected to boost the segment's growth throughout the forecast period.
In January 2023, Pacific Prime Thailand announced the partnership with HelpDeliver, a task-based home healthcare service that is connected to the internet and a market growth partner for Telehealth, Hospitals, Clinics, Medical Device Distributors, and Insurers. They provide RESMED Sleep Apnea Testing-Medicine solutions, GLUNOVO Continuous Glucose Monitoring-CGM for diabetes management, premium home healthcare, employee health-wellness services, and useful health services.
In October 2022, Dexcom introduced the Dexcom G7, a next-generation continuous glucose monitor (CGM), for diabetics two years of age and above. The Dexcom G7 improves on the Dexcom CGM by adding new features such as a 60 % smaller, all-in-one, discrete wearable and the quickest 30-minute sensor warm-up of any CGM on the market.